<DOC>
	<DOCNO>NCT02416570</DOCNO>
	<brief_summary>This study aim identify clarithromycin ( CLM ) potential widely available inexpensive treatment cachexia ( loss muscle mass ) people non-small cell lung cancer ( NSCLC ) . Half participant receive clarithromycin half receive placebo .</brief_summary>
	<brief_title>Is Clarithromycin Potential Treatment Cachexia People With Lung Cancer ?</brief_title>
	<detailed_description>Clarithromycin report significantly improve marker inflammation , body weight , need hospital admission survival 42 patient NSCLC . Compared patient receive best supportive care , receive Clarithromycin improved median survival ~8 month ( 535 vs. 277 day ) , stay home longer ( 439 vs. 139 day ) report adverse effect . In another study , 33 patient NSCLC give Clarithromycin 3 month compare match control group reduction IL-6 level correlate improvement body weight ( gain 4 vs. 1kg ) survival . Thus , reduce inflammation , Clarithromycin may impede cachectic process , preserve body weight , physical function independence increase survival . These study Clarithromycin NSCLC limitation , e.g . lack placebo-control , direct assessment lean body mass . This feasibility study obtain data inform viability design large randomise , double-blind , placebo-controlled , phase III study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Adults stage IV , pathologically confirm , NSCLC suitable for/declining/not tolerate 1st/2ndline palliative chemotherapy , follow completion 1st/2ndline palliative chemotherapy A likely prognosis ≥3 month . Cachexia basis follow , weight loss &gt; 5 % past 6 month , BMI &lt; 20kg/m2 weight loss &gt; 2 % , appendicular skeletal muscle index determine duel energy xray absorptiometry consistent sarcopenia weight loss &gt; 2 % . Systemic inflammation basis Creactive protein &gt; 10mg/L . Adequate renal function define creatinine ≤132micromol/L eGFR ≥30mL/min/1.73m2 Adequate liver function define follow parameter , bilirubin ≤25micromol/L , AST ALT ≤2 time upper limit normal , unless liver metastasis , case ≤5 time upper limit normal Prepared suspend , necessary , use certain statin and/or substitute use domperidone alternative antiemetic duration study ECOG Performance Status 3 4 Little food intake Weight loss &gt; 10 % 1 month &gt; 20 % total Known hypersensitivity clarithromycin Inability accurately measure QT interval , e.g . atrial fibrillation QTc prolongation &gt; 450 millisecond male , 470 millisecond female History ventricular arrhythmia Severe cardiac insufficiency ( NYHA class &gt; 2 ) Untreated hypokalaemia/hypomagnesaemia Active infection require antibiotic Current recent ( within last 4 week ) history Clostridium difficile , eat disorder , dysphagia , malabsorption diarrhoea Untreated adrenal thyroid disease Brain metastasis Use corticosteroids/progestogens Use chemotherapy , immunosuppressive , antiviral ( e.g . hepatitis C , HIV ) drug within 4 week Drugs contraindicate ( except certain statin temporarily suspend domperidone substitute alternative antiemetic ) avoid patient receive clarithromycin , either risk drugdrug interaction and/or prolong QT Pregnancy Breast Feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Clarithromycin</keyword>
</DOC>